Pioglitazone

Product Name: Pioglitazone

Synonyms: 5-[4-[2-(5-Ethyl-2-pyridinyl)ethoxy]benzyl]thiazolidine-2,4-dione;Pioglitazone (Actos);2,4-Thiazolidinedione,5-[[4-[2-(5-ethyl-2-pyridinyl)ethoxy]phenyl]Methyl]-;Pioglitazone 5-[[4-[2-(5-Ethylpyridin-2-yl)ethoxy]phenyl]methyl]-1,3-thiazolidine-2,4-dione;5-[4-[2-(5-ETHYL-2-PYRIDINYL)ETHOXY]PHENYL]METHYL-2,4-THIAZOLIDINEDIONE;5-(4-[2-(5-ETHYL-PYRIDIN-2-YL)-ETHOXY]-BENZYL)-THIAZOLIDINE-2,4-DIONE;Pioglitazone;PIOGLITAZONE HCL(5-[[4-[2-(5-ETHYLPYRIDIN-2-YL)ETHOXY]PHENYL]METHYL]THIAZOLIDINE-2,4-DIONE, HCL)

CAS: 111025-46-8

MF: C19H20N2O3S

MW: 356.44

EINECS: 601-029-7

Product Categories: APIS;LESCOL

Mol File: 111025-46-8.mol

Pioglitazone Structure

Pioglitazone Chemical Properties

Melting point 183-184 C

Boiling point 575.4±45.0 °C(Predicted)

density 1.260±0.06 g/cm3(Predicted)

form White to off-white solid.

pka 6.35±0.50(Predicted)

Safety Information

Hazard Codes F,C

Risk Statements 11-34

Safety Statements 16-26-36/37/39-45

Hazardous Substances Data 111025-46-8(Hazardous Substances Data)

MSDS Information

Provider Language

Pioglitazone English

Pioglitazone Usage And Synthesis

Uses antihyperlipidemic, HMGCoA reductase inhibitor

Definition ChEBI: A member of the class of thiazolidenediones that is 1,3-thiazolidine-2,4-dione substituted by a benzyl group at position 5 which in turn is substituted by a 2-(5-ethylpyridin-2-yl)ethoxy group at position 4 of the phenyl ring. It exhibits hypoglycemic acti ity.

Indications Pioglitazone is approved for use as monotherapy and in conjunction with metformin, sulfonylureas, and insulin. It is taken once a day with or without food. Though pioglitazone may also cause a small increase in low-density lipoprotein concentrations, there is usually a modest decrease in triglyceride levels, but it unclear whether this has any clinical significance or persists in the long term.

Brand name Actos (Takeda).

General Description Pioglitazone, (±)-5-[[4-[2-(5-ethyl-2-pyridinyl)ethoxy]phenyl]methyl]-2,4-thiazolidinedione (Actos),is an odorless, white, crystalline powder that must be convertedto a salt such as its hydrochloride before it will haveany water solubility. Although the molecule contains one chiralcenter, the compound is used as the racemic mixture. Thisis primarily a result of the in vivo interconversion of the twoenantiomers. Thus, there are no differences in the pharmacologicalactivity of the two enantiomers.